$MRK

124 stories mentioning MRKUpdated 16d ago

Every FINWIRES story that references MRK, newest first.

What are analysts saying about MRK?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on MRK?

Sector Update: Health Care Stocks Softer Tuesday Afternoon

Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) decreased 0.7%.In corporate news, Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.9%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 8%.Quest Diagnostics (DGX) shares popped 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.

$DGX$MRK$UNH

Wire146d ago

Leerink Partners Cuts Merck Price Target to $127 From $129, Maintains Outperform Rating

Merck (MRK) has an average rating of overweight and mean price target of $130.88, according to analysts polled by FactSet.Price: $112.78, Change: $-4.32, Percent Change: -3.69%

$MRK

Sectors150d ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) gained 1.6%.In corporate news, Abbott Laboratories' (ABT) end-markets remain healthy despite a lower 2026 organic revenue guidance amid fiscal Q1 challenges and mixed performance, RBC Capital Markets said in a note. Abbott shares rose 1.7%.Merck (MRK) shares added 2.8% after it said Friday that the European Commission has approved Enflonsia to prevent respiratory tract disease in newborns and infants.Kura Oncology (KURA) shares jumped past 9% after it said Friday that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.Psyence Biomedical (PBM) shares surged 30% after it acknowledged recent reports saying that the US administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder, addiction, and other serious neurological and mental health conditions. Through its investment in PsyLabs, Psyence has established a position in the manufacturing of ibogaine and ibogaine derivatives, it said.

$ABT$KURA$MRK$PBM

Sectors150d ago

Sector Update: Health Care Stocks Higher Friday Afternoon

Health care stocks climbed Friday afternoon, with the NYSE Health Care Index rising 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) advanced 1.4%.In corporate news, Merck (MRK) shares rose 2.3% after it said Friday that the European Commission has approved Enflonsia to prevent respiratory tract disease in newborns and infants.Kura Oncology (KURA) shares jumped nearly 7% after it said Friday that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.Psyence Biomedical (PBM) shares surged 66% after it acknowledged recent reports saying that the US administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder, addiction, and other serious neurological and mental health conditions. Through its investment in PsyLabs, Psyence has established a position in the manufacturing of ibogaine and ibogaine derivatives, it said.

$KURA$MRK$PBM

Showing 121-124 of 124

Track with the FINWIRES app suite

FolioX

Track MRK in your portfolio

WheelAI

Analyze MRK options with the wheel strategy

StockInsider

See market sentiment on MRK